Clinical Trials Logo

Filter by:
NCT ID: NCT04006457 Active, not recruiting - Alopecia Areata Clinical Trials

Long-Term PF-06651600 for the Treatment of Alopecia Areata

ALLEGRO-LT
Start date: July 18, 2019
Phase: Phase 3
Study type: Interventional

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug. A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.

NCT ID: NCT04006405 Recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

AUR87A
Start date: January 10, 2020
Phase:
Study type: Observational

AUR87A is an observational prospective multicenter diagnostics test cohort study for detection of renal cell carcinoma recurrence as determined by the reference standard, which is imaging using computed tomography (CT) of the chest and abdomen at defined intervals after primary surgery.

NCT ID: NCT04005352 Completed - Clinical trials for Age-related Macular Degeneration

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

TALON
Start date: September 25, 2019
Phase: Phase 3
Study type: Interventional

This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.

NCT ID: NCT04005287 Completed - Clinical trials for Peripheral Neuropathy

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in subjects with T2DM with peripheral neuropathy.

NCT ID: NCT04005235 Terminated - Paresis Clinical Trials

FOT Assessment of Hemi-diaphragm Dysfunction After Upper Extremity Nerve Blocks

Start date: July 31, 2019
Phase:
Study type: Observational

Upper extremity nerve blocks of the brachial plexus using local anesthetic can inadvertently affect the ipsilateral phrenic nerve and result in hemidiaphragm dysfunction. Ultrasonography is often used to assess for hemidiaphragm dysfunction after brachial plexus nerve blocks. Alternately, post-operative chest x-rays can also be used to document unilateral hemidiaphragm elevation secondary to phrenic nerve dysfunction. Newly developed passive breathing testing devices (Forced Oscillometry Technique - FOT) use small composite pressure waveforms (5-37Hz) imposed on top of normal breathing and measure the resulting reflected oscillations to assess the mechanical properties of the lungs. The lung resistance R(f) and reactance X(f) are automatically mathematically derived from the reflected pressure waveforms returning from the respiratory system to the FOT device. In this study, we will assess if FOT can be used to detect changes in lung mechanics (lung resistance R(f) and reactance X(f)) after ultrasound proven hemidiaphragm dysfunction secondary to brachial plexus nerve block.

NCT ID: NCT04005196 Not yet recruiting - Delirium Clinical Trials

EEG Phase Synchrony, Sedation and Delirium in the CVICU

SOS
Start date: September 1, 2019
Phase:
Study type: Observational

EEG phase synchrony and variability has had limited investigation during transition from coma to wakefulness in response to sedation and analgesia. Studying changes in phase synchrony and variability during and after sedative-induced coma is an exciting opportunity to better understand EEG changes during transitions in states of arousal. It is expected that consciousness should be higher in entropy and greater in complexity in the number of configurations of pairwise connections as compared to sedative-induced coma. If sufficiently sensitive, it may be possible to identify states of lower entropy and fewer configurations when patient are aroused but with altered sensorium (e.g. delirium).

NCT ID: NCT04005183 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Renal Cell Carcinoma Microenvironment Discovery Project

REMEDY
Start date: May 6, 2019
Phase:
Study type: Observational

This study will obtain tumor samples from nephrectomy specimens in a multi-regional fashion and subject them to integrated genomics, proteomics, pathological, and radiological assessment. The goal is to better understand the the molecular basis for how various cells within the tumor microenvironment act in a coordinated manner to facilitate tumor progression and therapy resistance. Our ultimate aim is to leverage this data resource to identify novel therapeutic targets and biomarkers to improve the clinical management of this disease.

NCT ID: NCT04004858 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Margin Reduction to Reduce Acute Rectal Toxicity (PROTRACT)

PROTRACT
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

The objectives of this study are: 1. Retrospectively validate a reduced margin schema for intermediate risk prostate hypofractionated VMAT treatments 2. Demonstrate in a prospective pilot clinical trial that patients planned and treated with the reduced margin schema will have reduced acute rectal toxicity

NCT ID: NCT04004676 Recruiting - Ketosis Clinical Trials

Ketone Supplementation, Glycogen Replenishment and Time Trial Performance Following Glycogen Lowering Exercise

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

20 healthy trained males will volunteer to participate in this study. there will be 2 treatments: Carbohydrate- ketone supplementation and carbohydrate alone. The purpose of this study is to evaluate the effect of glucose-ketone supplementation on a 20 km cycling time trial with a 2-hour feeding during a 4-hour recovery period following glycogen depleting exercise.

NCT ID: NCT04004611 Completed - Ulcerative Colitis Clinical Trials

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

SHINE-1
Start date: May 18, 2020
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab. The study lasted about 52 weeks and included up to 18 visits.